Dual-Action Compounds for Oral Mucositis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for oral mucositis associated with chemotherapy and radiation therapy are inadequate, leading to significant pain, debilitation, and increased healthcare costs, with limited effective pharmaceutical options available for prevention or treatment.
Innovation Solution
Administration of specific compounds, such as those represented by Formulas I to XXV, which possess dual anti-inflammatory and antimicrobial properties to address the multifactorial pathogenesis of oral mucositis, providing a therapeutically effective amount to prevent or lessen the clinical course of the disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for oral mucositis, then existing pharmaceutical options are limited, but treatment effectiveness is inadequate leading to significant pain and debilitation
Solution Approach 1:
The invention addresses the multifactorial pathogenesis of mucositis by segmenting the treatment approach into two distinct functional components: anti-inflammatory activity and antimicrobial activity. The compounds are designed to simultaneously target inflammatory mediators (TNF-α, IL-1β, IL-6) and bacterial components (LPS, LTA) separately, thereby providing comprehensive treatment coverage that overcomes the limitation of single-function pharmaceuticals
Solution Approach 2:
The compounds disclosed in this patent exhibit multi-functionality by simultaneously demonstrating both anti-inflammatory and antimicrobial properties. This dual functionality allows a single pharmaceutical agent to address multiple aspects of mucositis pathogenesis, thereby expanding the available treatment options and improving overall treatment effectiveness
2Object-affected harmful factors
If ulcerations are present in mucositis, then portals of entry for oral bacteria are created, but this leads to sepsis or bacteremia
Solution Approach 1:
The invention applies preliminary anti-action by providing compounds that prevent bacterial colonization and infection before sepsis or bacteremia can develop. The antimicrobial activity of the compounds acts prophylactically to block bacterial entry through ulcerations, while the anti-inflammatory activity prevents the cascade that would lead to systemic infection, thereby ensuring patient safety
3Ease of operation
If mucositis is treated with current methods, then quality of life is affected, but healthcare costs increase due to increased hospital stays
Solution Approach 1:
The invention employs preliminary action by administering compounds that prevent the development of severe mucositis and its complications before they occur. By addressing the inflammatory and microbial components early in the disease process, the treatment prevents the need for extended hospitalizations and intensive care, thereby reducing healthcare resource consumption while maintaining quality of life
Data Source
AI summary
The present invention provides methods for treating and/or preventing mucostitis with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, or compositions comprising the same.